Context Navigation

← Previous Revision
Latest Revision
Next Revision →
Blame
Revision Log

source: qrda/C0Q/trunk/kids/C0Q1.03.DONTUSE@ 1485

Last change on this file since 1485 was 1485, checked in by Sam Habiel, 12 years ago
Temporary Kids builds for Reminder packaging
File size: 68.4 KB

Line
1	KIDS Distribution saved on Jul 13, 2012@16:39:48
2	DFGHJKL
3	KIDS:C0Q1.03^
4
5	INSTALL NAME
6	C0Q1.03
7	"BLD",7936,0)
8	C0Q1.03^QUALITY MEASURES^0^3120713^y
9	"BLD",7936,1,0)
10	^^5^5^3120713^
11	"BLD",7936,1,1,0)
12	Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
13	"BLD",7936,1,2,0)
14	2.0.
15	"BLD",7936,1,3,0)
16
17	"BLD",7936,1,4,0)
18	Contains updated C0Q QUALITY MEASURES file containing the appropriate
19	"BLD",7936,1,5,0)
20	rule sets to use after each measure.
21	"BLD",7936,4,0)
22	^9.64PA^1130580001.101^1
23	"BLD",7936,4,1130580001.101,0)
24	1130580001.101
25	"BLD",7936,4,1130580001.101,222)
26	y^y^f^^y^^y^o^n
27	"BLD",7936,4,"B",1130580001.101,1130580001.101)
28
29	"BLD",7936,6.3)
30	2
31	"BLD",7936,"ABPKG")
32	n
33	"BLD",7936,"KRN",0)
34	^9.67PA^779.2^20
35	"BLD",7936,"KRN",.4,0)
36	.4
37	"BLD",7936,"KRN",.401,0)
38	.401
39	"BLD",7936,"KRN",.402,0)
40	.402
41	"BLD",7936,"KRN",.403,0)
42	.403
43	"BLD",7936,"KRN",.5,0)
44	.5
45	"BLD",7936,"KRN",.84,0)
46	.84
47	"BLD",7936,"KRN",3.6,0)
48	3.6
49	"BLD",7936,"KRN",3.8,0)
50	3.8
51	"BLD",7936,"KRN",9.2,0)
52	9.2
53	"BLD",7936,"KRN",9.8,0)
54	9.8
55	"BLD",7936,"KRN",19,0)
56	19
57	"BLD",7936,"KRN",19.1,0)
58	19.1
59	"BLD",7936,"KRN",101,0)
60	101
61	"BLD",7936,"KRN",409.61,0)
62	409.61
63	"BLD",7936,"KRN",771,0)
64	771
65	"BLD",7936,"KRN",779.2,0)
66	779.2
67	"BLD",7936,"KRN",870,0)
68	870
69	"BLD",7936,"KRN",8989.51,0)
70	8989.51
71	"BLD",7936,"KRN",8989.52,0)
72	8989.52
73	"BLD",7936,"KRN",8994,0)
74	8994
75	"BLD",7936,"KRN","B",.4,.4)
76
77	"BLD",7936,"KRN","B",.401,.401)
78
79	"BLD",7936,"KRN","B",.402,.402)
80
81	"BLD",7936,"KRN","B",.403,.403)
82
83	"BLD",7936,"KRN","B",.5,.5)
84
85	"BLD",7936,"KRN","B",.84,.84)
86
87	"BLD",7936,"KRN","B",3.6,3.6)
88
89	"BLD",7936,"KRN","B",3.8,3.8)
90
91	"BLD",7936,"KRN","B",9.2,9.2)
92
93	"BLD",7936,"KRN","B",9.8,9.8)
94
95	"BLD",7936,"KRN","B",19,19)
96
97	"BLD",7936,"KRN","B",19.1,19.1)
98
99	"BLD",7936,"KRN","B",101,101)
100
101	"BLD",7936,"KRN","B",409.61,409.61)
102
103	"BLD",7936,"KRN","B",771,771)
104
105	"BLD",7936,"KRN","B",779.2,779.2)
106
107	"BLD",7936,"KRN","B",870,870)
108
109	"BLD",7936,"KRN","B",8989.51,8989.51)
110
111	"BLD",7936,"KRN","B",8989.52,8989.52)
112
113	"BLD",7936,"KRN","B",8994,8994)
114
115	"BLD",7936,"QUES",0)
116	^9.62^^
117	"BLD",7936,"REQB",0)
118	^9.611^2^2
119	"BLD",7936,"REQB",1,0)
120	C0Q1.02^2
121	"BLD",7936,"REQB",2,0)
122	QUALITY MEASURES 1.0^2
123	"BLD",7936,"REQB","B","C0Q1.02",1)
124
125	"BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2)
126
127	"DATA",1130580001.101,1,0)
128	M1^^^2.16.840.1.113883.3.249.11.2
129	"DATA",1130580001.101,1,1)
130	CMS Measure #1: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
131	"DATA",1130580001.101,1,4)
132	PQRI-1
133	"DATA",1130580001.101,1,5)
134	Hemoglobin A1c Poor Control in Diabetes Mellitus
135	"DATA",1130580001.101,1,6,0)
136	^^2^2^3101013^
137	"DATA",1130580001.101,1,6,1,0)
138	Percentage of patients 18 through 75 years with diabetes melli
139	"DATA",1130580001.101,1,6,2,0)
140	tus who had most recent hemoglobin A1C greater than 9.0%
141	"DATA",1130580001.101,1,7)
142	^^^^
143	"DATA",1130580001.101,2,0)
144	M5^^^2.16.840.1.113883.3.249.11.5
145	"DATA",1130580001.101,2,1)
146	CMS Measure #5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
147	"DATA",1130580001.101,2,4)
148	PQRI-5
149	"DATA",1130580001.101,2,5)
150	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
151	"DATA",1130580001.101,2,6,0)
152	^^2^2^3101013^
153	"DATA",1130580001.101,2,6,1,0)
154	Percentage of patients 18 years and older with a diagnosis of
155	"DATA",1130580001.101,2,6,2,0)
156	heart failure and LVSD who were prescribed an ACE inhbitor or ARB therapy
157	"DATA",1130580001.101,2,7)
158	^^^^
159	"DATA",1130580001.101,3,0)
160	M112^^^2.16.840.1.113883.3.249.11.9
161	"DATA",1130580001.101,3,1)
162	Measure #112: Preventive Care and Screening: Screening Mammography
163	"DATA",1130580001.101,3,4)
164	PQRI-112
165	"DATA",1130580001.101,3,5)
166	Screening Mammography
167	"DATA",1130580001.101,3,6,0)
168	^1130580001.111^2^2^3101014^^
169	"DATA",1130580001.101,3,6,1,0)
170	Percentage of womaen aged 40 through 69 years who had a mammog
171	"DATA",1130580001.101,3,6,2,0)
172	ram to screen for breast cancer within 24 months
173	"DATA",1130580001.101,3,7)
174	^^^^
175	"DATA",1130580001.101,4,0)
176	M124^^^2.16.840.1.113883.3.249.11.11
177	"DATA",1130580001.101,4,1)
178	Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
179	"DATA",1130580001.101,4,4)
180	PQRI-124
181	"DATA",1130580001.101,4,5)
182	Adoption/Use of Electronic Health Records (EHR)
183	"DATA",1130580001.101,4,6,0)
184	^^3^3^3101013^
185	"DATA",1130580001.101,4,6,1,0)
186	Documents whether provider has adopted and is using health inf
187	"DATA",1130580001.101,4,6,2,0)
188	ormation technology. To qualify, the provider must havea adopted and be
189	"DATA",1130580001.101,4,6,3,0)
190	using a certified/qualified electronic health record (EHR)
191	"DATA",1130580001.101,4,7)
192	^^^^
193	"DATA",1130580001.101,5,0)
194	M128^^^2.16.840.1.113883.3.249.11.54
195	"DATA",1130580001.101,5,1)
196	Measure #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
197	"DATA",1130580001.101,5,4)
198	PQRI-128
199	"DATA",1130580001.101,5,5)
200	Body Mass Index (BMI) Screening and Follow-Up
201	"DATA",1130580001.101,5,6,0)
202	^1130580001.111^5^5^3101014^^
203	"DATA",1130580001.101,5,6,1,0)
204	Percentage of patients aged 18 yesrs and older with a calculate BMI in
205	"DATA",1130580001.101,5,6,2,0)
206	the past 6 months or during the current visit documented in the medical
207	"DATA",1130580001.101,5,6,3,0)
208	record and if the most recent BMI is ourtide parameters, a follow-up plan
209	"DATA",1130580001.101,5,6,4,0)
210	is documented. Ages 65 and older BMI equal to or greater than 30 or less
211	"DATA",1130580001.101,5,6,5,0)
212	than 22 and ages 18-64, BMI greater than or equal to 25 or less than 18.5
213	"DATA",1130580001.101,5,7)
214	^^^^
215	"DATA",1130580001.101,6,0)
216	M47^^^2.16.840.1.113883.3.249.11.52
217	"DATA",1130580001.101,6,1)
218	Measure #47: Advance Care Plan
219	"DATA",1130580001.101,6,4)
220	PQRI-47
221	"DATA",1130580001.101,6,5)
222	Advance Care Plan
223	"DATA",1130580001.101,6,6,0)
224	^1130580001.111^5^5^3101014^^^
225	"DATA",1130580001.101,6,6,1,0)
226	Percentage of patients age 65 and older who have an advanced care plan or
227	"DATA",1130580001.101,6,6,2,0)
228	surrogate decision maker documented in the medical record or documented
229	"DATA",1130580001.101,6,6,3,0)
230	in the medical record that an advance care plan was discussed but the
231	"DATA",1130580001.101,6,6,4,0)
232	patient did not wish or was not able to name a surrogate decision maker
233	"DATA",1130580001.101,6,6,5,0)
234	or provide an advance care plan.
235	"DATA",1130580001.101,6,7)
236	^^^^
237	"DATA",1130580001.101,7,0)
238	M48^^^2.16.840.1.113883.3.249.11.53
239	"DATA",1130580001.101,7,1)
240	Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
241	"DATA",1130580001.101,7,4)
242	PQRI-48
243	"DATA",1130580001.101,7,5)
244	Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
245	"DATA",1130580001.101,7,6,0)
246	^^3^3^3101013^
247	"DATA",1130580001.101,7,6,1,0)
248	Percentage of patients equal to or older than 65 years of age at the
249	"DATA",1130580001.101,7,6,2,0)
250	beginning of the measurement perion who were assesed for the presence or
251	"DATA",1130580001.101,7,6,3,0)
252	absence of urinary incontinence within 12 months
253	"DATA",1130580001.101,7,7)
254	^^^^
255	"DATA",1130580001.101,8,0)
256	M2^^^2.16.840.1.113883.3.249.11.3
257	"DATA",1130580001.101,8,1)
258	Measure #2: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
259	"DATA",1130580001.101,8,4)
260	PQRI-2
261	"DATA",1130580001.101,8,5)
262	Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
263	"DATA",1130580001.101,8,6,0)
264	^^2^2^3101013^
265	"DATA",1130580001.101,8,6,1,0)
266	Percentage of patients 18 through 75 years with diabetes melli
267	"DATA",1130580001.101,8,6,2,0)
268	tus who had most recent LDL-C level in control (less than 100 mg./dL)
269	"DATA",1130580001.101,8,7)
270	^^^^
271	"DATA",1130580001.101,9,0)
272	M3^^^2.16.840.1.113883.3.249.11.4
273	"DATA",1130580001.101,9,1)
274	CMS Measure #3: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus - QRDA Cat I template
275	"DATA",1130580001.101,9,4)
276	PQRI-3
277	"DATA",1130580001.101,9,5)
278	High Blood Pressure Control in Diabetes Mellitus
279	"DATA",1130580001.101,9,6,0)
280	^^2^2^3101013^
281	"DATA",1130580001.101,9,6,1,0)
282	Percentage of patients 18 through 75 years with diabetes melli
283	"DATA",1130580001.101,9,6,2,0)
284	tus who had most recent blood pressure in control (less than 140/80 mmHg)
285	"DATA",1130580001.101,9,7)
286	^^^^
287	"DATA",1130580001.101,10,0)
288	M7^^^2.16.840.1.113883.3.249.11.6
289	"DATA",1130580001.101,10,1)
290	CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
291	"DATA",1130580001.101,10,4)
292	PQRI-7
293	"DATA",1130580001.101,10,5)
294	Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
295	"DATA",1130580001.101,10,6,0)
296	^^3^3^3101013^
297	"DATA",1130580001.101,10,6,1,0)
298	Percentage of patients aged 18 years and older with a diagnosis of
299	"DATA",1130580001.101,10,6,2,0)
300	coronary artery disease and a prior MI who where prescribed beta-blocker
301	"DATA",1130580001.101,10,6,3,0)
302	therapy
303	"DATA",1130580001.101,10,7)
304	^^^^
305	"DATA",1130580001.101,11,0)
306	M110^^^2.16.840.1.113883.3.249.11.7
307	"DATA",1130580001.101,11,1)
308	Measure #110: Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years
309	"DATA",1130580001.101,11,4)
310	PQRI-110
311	"DATA",1130580001.101,11,5)
312	Influenza Immunization for Patients >= 50 Years
313	"DATA",1130580001.101,11,6,0)
314	^1130580001.111^2^2^3101014^^
315	"DATA",1130580001.101,11,6,1,0)
316	Percentage of patients aged 50 years and older who received an
317	"DATA",1130580001.101,11,6,2,0)
318	influenza immunization during the flu season (September through February)
319	"DATA",1130580001.101,11,7)
320	^^^^
321	"DATA",1130580001.101,12,0)
322	M111^^^2.16.840.1.113883.3.249.11.8
323	"DATA",1130580001.101,12,1)
324	Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
325	"DATA",1130580001.101,12,4)
326	PQRI-111
327	"DATA",1130580001.101,12,5)
328	Pneumonia Vaccination for Patients 65 Years and Older
329	"DATA",1130580001.101,12,6,0)
330	^^2^2^3101013^
331	"DATA",1130580001.101,12,6,1,0)
332	Percentage of patients afed 65 years and older who have ever r
333	"DATA",1130580001.101,12,6,2,0)
334	eceived a pneumoccal vaccine
335	"DATA",1130580001.101,12,7)
336	^^^^
337	"DATA",1130580001.101,13,0)
338	M113^^^2.16.840.1.113883.3.249.11.10
339	"DATA",1130580001.101,13,1)
340	Measure #113: Preventive Care and Screening: Colorectal Cancer Screening
341	"DATA",1130580001.101,13,4)
342	PQRI-113
343	"DATA",1130580001.101,13,5)
344	Colorectal Cancer Screening
345	"DATA",1130580001.101,13,6,0)
346	^^2^2^3101013^
347	"DATA",1130580001.101,13,6,1,0)
348	Percentage of patients aged 50 through 80 who received the app
349	"DATA",1130580001.101,13,6,2,0)
350	ropriate colorectal cancer screening
351	"DATA",1130580001.101,13,7)
352	^^^^
353	"DATA",1130580001.101,14,0)
354	M39^^^2.16.840.1.113883.3.249.11.51
355	"DATA",1130580001.101,14,1)
356	Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
357	"DATA",1130580001.101,14,4)
358	PQRI-39
359	"DATA",1130580001.101,14,5)
360	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
361	"DATA",1130580001.101,14,6,0)
362	^^3^3^3101013^
363	"DATA",1130580001.101,14,6,1,0)
364	Percentage of patients who had a DXA measurement ordered or pe
365	"DATA",1130580001.101,14,6,2,0)
366	rformed at least once since age 60 or pharmacologic therapy prescribed
367	"DATA",1130580001.101,14,6,3,0)
368	within 12 months before the end of the measurement period
369	"DATA",1130580001.101,14,7)
370	^^^^
371	"DATA",1130580001.101,16,0)
372	M173^^^2.16.840.1.113883.3.249.11.55
373	"DATA",1130580001.101,16,1)
374	Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
375	"DATA",1130580001.101,16,4)
376	PQRI-173
377	"DATA",1130580001.101,16,5)
378	Preventive Care and Screening: Unhealthy Alcohol Use - Screening
379	"DATA",1130580001.101,16,6,0)
380	^^2^2^3101013^
381	"DATA",1130580001.101,16,6,1,0)
382	Percentage of patients aged 18 years and older who were screen
383	"DATA",1130580001.101,16,6,2,0)
384	ed for unhealthy alcohol use using a systematic method within 24 months
385	"DATA",1130580001.101,16,7)
386	^^^^
387	"DATA",1130580001.101,17,0)
388	M0013^^^2.16.840.1.113883.3.249.11.56
389	"DATA",1130580001.101,17,1)
390	Measure #0013: Hypertension (HTN): Blood Pressure Measurement - QRDA Cat I template
391	"DATA",1130580001.101,17,4)
392	PQRI-13
393	"DATA",1130580001.101,17,5)
394	Hypertension (HTN): Blood Pressure Measurement
395	"DATA",1130580001.101,17,6,0)
396	^1130580001.111^3^3^3110412^^
397	"DATA",1130580001.101,17,6,1,0)
398	Percentage of patients aged 18 years and older with a diagnosi
399	"DATA",1130580001.101,17,6,2,0)
400	s of hypertension in the beginning of the measurement period with a blood
401	"DATA",1130580001.101,17,6,3,0)
402	pressure recorded
403	"DATA",1130580001.101,17,7)
404	^^^^
405	"DATA",1130580001.101,18,0)
406	M0022^^^2.16.840.1.113883.3.249.11.57
407	"DATA",1130580001.101,18,1)
408	Measure #0022: Drugs to be avoided in the Elderly
409	"DATA",1130580001.101,18,4)
410	PQRI-22
411	"DATA",1130580001.101,18,5)
412	Drugs to be avoided in the elderly
413	"DATA",1130580001.101,18,6,0)
414	^^2^2^3101013^
415	"DATA",1130580001.101,18,6,1,0)
416	Percentage of patients aged 65 years and older who received at least one
417	"DATA",1130580001.101,18,6,2,0)
418	drug to be avoided in the elderly in the measurement period
419	"DATA",1130580001.101,18,7)
420	^^^^
421	"DATA",1130580001.101,19,0)
422	M0028^^^2.16.840.1.113883.3.249.11.59
423	"DATA",1130580001.101,19,1)
424	Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
425	"DATA",1130580001.101,19,4)
426	PQRI-28
427	"DATA",1130580001.101,19,5)
428	Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
429	"DATA",1130580001.101,19,6,0)
430	^^4^4^3101013^
431	"DATA",1130580001.101,19,6,1,0)
432	Percentage of patients aged 18 years of older who were screene
433	"DATA",1130580001.101,19,6,2,0)
434	d about tobacco use at least once during the two year measurement period
435	"DATA",1130580001.101,19,6,3,0)
436	AND who received smoking cessation counseling if identified as a tobacco
437	"DATA",1130580001.101,19,6,4,0)
438	user
439	"DATA",1130580001.101,19,7)
440	^^^^
441	"DATA",1130580001.101,20,0)
442	M0038^^^2.16.840.1.113883.3.249.11.60
443	"DATA",1130580001.101,20,1)
444	Measure #0038: Childhood Immunization Status
445	"DATA",1130580001.101,20,4)
446	PQRI-38
447	"DATA",1130580001.101,20,5)
448	Childhood immumnization status
449	"DATA",1130580001.101,20,6,0)
450	^^4^4^3101013^
451	"DATA",1130580001.101,20,6,1,0)
452	Percentage of children who turn two years of age during the me
453	"DATA",1130580001.101,20,6,2,0)
454	asurement period who have had 4 DTaP/DT, 3 IPV, 1 MMR and 3 H influenza
455	"DATA",1130580001.101,20,6,3,0)
456	type B, 3 hepatitis B, 1 chicken pox vaccine (VZV) and 4 pneumoccal
457	"DATA",1130580001.101,20,6,4,0)
458	conjugate vaccines by their second birthday
459	"DATA",1130580001.101,20,7)
460	^^^^
461	"DATA",1130580001.101,21,0)
462	M0024^^
463	"DATA",1130580001.101,21,7)
464	^^^^
465	"DATA",1130580001.101,22,0)
466	TEST M0028A^^^2.16.840.1.113883.3.249.11.59
467	"DATA",1130580001.101,22,1)
468	Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
469	"DATA",1130580001.101,22,4)
470	PQRI-28
471	"DATA",1130580001.101,22,5)
472	Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
473	"DATA",1130580001.101,22,6,0)
474	^1130580001.111^4^4^3110427^^^^
475	"DATA",1130580001.101,22,6,1,0)
476	Percentage of patients aged 18 years of older who were screene
477	"DATA",1130580001.101,22,6,2,0)
478	d about tobacco use at least once during the two year measurement period
479	"DATA",1130580001.101,22,6,3,0)
480	AND who received smoking cessation counseling if identified as a tobacco
481	"DATA",1130580001.101,22,6,4,0)
482	user
483	"DATA",1130580001.101,22,7)
484	^^^^
485	"DATA",1130580001.101,23,0)
486	MU HOS NQF 0495^^
487	"DATA",1130580001.101,23,1)
488	ED THROUGHPUT ARRIVAL TO DEPARTURE
489	"DATA",1130580001.101,23,5)
490	ED THROUGHPUT ARRIVAL TO DEPARTURE
491	"DATA",1130580001.101,23,6,0)
492	^1130580001.111^3^3^3110430^^^^
493	"DATA",1130580001.101,23,6,1,0)
494	Median time from emergency department arrival to time of departure from
495	"DATA",1130580001.101,23,6,2,0)
496	the emergency room for patients admitted to the facility from the
497	"DATA",1130580001.101,23,6,3,0)
498	emergency department
499	"DATA",1130580001.101,23,7)
500	NQF0495^^^^
501	"DATA",1130580001.101,24,0)
502	MU HOS NQF 0497^^
503	"DATA",1130580001.101,24,1)
504	ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
505	"DATA",1130580001.101,24,5)
506	ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
507	"DATA",1130580001.101,24,6,0)
508	^^3^3^3110430^
509	"DATA",1130580001.101,24,6,1,0)
510	Median time from admit decision time to time of departure from the
511	"DATA",1130580001.101,24,6,2,0)
512	emergency department of emergency department patients admitted to
513	"DATA",1130580001.101,24,6,3,0)
514	inpatient status
515	"DATA",1130580001.101,24,7)
516	NQF0497^^^^
517	"DATA",1130580001.101,25,0)
518	MU HOS NQF 0435^^
519	"DATA",1130580001.101,25,1)
520	Ischemic stroke.Discharge on anti-thrombotics
521	"DATA",1130580001.101,25,5)
522	Ischemic stroke.Discharge on anti-thrombotic
523	"DATA",1130580001.101,25,6,0)
524	^^2^2^3110430^
525	"DATA",1130580001.101,25,6,1,0)
526	Ischemic stroke patients prescribed antithrombotic therapy at hospital
527	"DATA",1130580001.101,25,6,2,0)
528	discharge
529	"DATA",1130580001.101,25,7)
530	NQF0435^^^^
531	"DATA",1130580001.101,26,0)
532	MU HOS NQF 0436^^
533	"DATA",1130580001.101,26,1)
534	Ischemic stroke.Anticoagulation for A-fib/flutter
535	"DATA",1130580001.101,26,5)
536	Ischemic stroke.Anticoagulation for A-fib/flutter
537	"DATA",1130580001.101,26,6,0)
538	^1130580001.111^2^2^3110430^^^
539	"DATA",1130580001.101,26,6,1,0)
540	Ischemic stroke patients with atrial fibrillation/flutter who are
541	"DATA",1130580001.101,26,6,2,0)
542	prescribed anticoagulation therapy at hospital discharge
543	"DATA",1130580001.101,26,7)
544	NQF0436^^^^
545	"DATA",1130580001.101,27,0)
546	MU HOS NQF 0437^^
547	"DATA",1130580001.101,27,1)
548	Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
549	"DATA",1130580001.101,27,5)
550	Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
551	"DATA",1130580001.101,27,6,0)
552	^^3^3^3110430^
553	"DATA",1130580001.101,27,6,1,0)
554	Acute ischemic stroke patients who arrive at this hospital within 2
555	"DATA",1130580001.101,27,6,2,0)
556	hours of time last known well and for whom IV t-PA was initiated at this
557	"DATA",1130580001.101,27,6,3,0)
558	hospital within 3 hours of time last known well.
559	"DATA",1130580001.101,27,7)
560	NQF0437^^^^
561	"DATA",1130580001.101,28,0)
562	MU HOS NQF 0438^^
563	"DATA",1130580001.101,28,1)
564	Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
565	"DATA",1130580001.101,28,5)
566	Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
567	"DATA",1130580001.101,28,6,0)
568	^^2^2^3110430^
569	"DATA",1130580001.101,28,6,1,0)
570	Ischemic stroke patients administered antithrombotic therapy by the
571	"DATA",1130580001.101,28,6,2,0)
572	end of hospital day 2.
573	"DATA",1130580001.101,28,7)
574	NQF0438^^^^
575	"DATA",1130580001.101,29,0)
576	MU HOS NQF 0439^^
577	"DATA",1130580001.101,29,1)
578	Ischemic stroke.Discharge on statins
579	"DATA",1130580001.101,29,5)
580	Ischemic stroke.Discharge on statins
581	"DATA",1130580001.101,29,6,0)
582	^^3^3^3110430^
583	"DATA",1130580001.101,29,6,1,0)
584	Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or,
585	"DATA",1130580001.101,29,6,2,0)
586	who were on a lipid-lowering medication prior to hospital arrival are
587	"DATA",1130580001.101,29,6,3,0)
588	prescribed statin medication at hospital discharge
589	"DATA",1130580001.101,29,7)
590	NQF0439^^^^
591	"DATA",1130580001.101,30,0)
592	MU HOS NQF 0440^^
593	"DATA",1130580001.101,30,1)
594	Ischemic or hemorrhagic stroke.Stroke education
595	"DATA",1130580001.101,30,5)
596	Ischemic or hemorrhagic stroke.Stroke education
597	"DATA",1130580001.101,30,6,0)
598	^^5^5^3110430^
599	"DATA",1130580001.101,30,6,1,0)
600	Ischemic or hemorrhagic stroke patients or their caregivers who were
601	"DATA",1130580001.101,30,6,2,0)
602	given educational materials during the hospital stay addressing all of the
603	"DATA",1130580001.101,30,6,3,0)
604	following: activation of emergency medical system, need for follow-up
605	"DATA",1130580001.101,30,6,4,0)
606	after discharge, medications prescribed at discharge, risk factors for
607	"DATA",1130580001.101,30,6,5,0)
608	stroke, and warning signs and symptoms of stroke.
609	"DATA",1130580001.101,30,7)
610	NQF0440^^^^
611	"DATA",1130580001.101,31,0)
612	MU HOS NQF 0441^^
613	"DATA",1130580001.101,31,1)
614	Ischemic or hemorrhagic stroke.Rehabilitation assessment
615	"DATA",1130580001.101,31,5)
616	Ischemic or hemorrhagic stroke.Rehabilitation assessment
617	"DATA",1130580001.101,31,6,0)
618	^^2^2^3110430^
619	"DATA",1130580001.101,31,6,1,0)
620	Ischemic or hemorrhagic stroke patients who were assessed for
621	"DATA",1130580001.101,31,6,2,0)
622	rehabilitation services.
623	"DATA",1130580001.101,31,7)
624	NQF0441^^^^
625	"DATA",1130580001.101,32,0)
626	MU HOS NQF 0371^^
627	"DATA",1130580001.101,32,1)
628	VTE prophylaxis within 24 hours of arrival
629	"DATA",1130580001.101,32,5)
630	VTE prophylaxis within 24 hours of arrival
631	"DATA",1130580001.101,32,6,0)
632	^^4^4^3110430^
633	"DATA",1130580001.101,32,6,1,0)
634	This measure assesses the number of patients who received VTE prophylaxis
635	"DATA",1130580001.101,32,6,2,0)
636	or have documentation why no VTE prophylaxis was given the day of or the
637	"DATA",1130580001.101,32,6,3,0)
638	day after hospital admission or surgery end date for surgeries that start
639	"DATA",1130580001.101,32,6,4,0)
640	the day of or the day after hospital admission.
641	"DATA",1130580001.101,32,7)
642	NQF0371^^^^
643	"DATA",1130580001.101,33,0)
644	MU HOS NQF 0372^^
645	"DATA",1130580001.101,33,1)
646	ICU VTE prophylaxis
647	"DATA",1130580001.101,33,5)
648	ICU VTE prophylaxis
649	"DATA",1130580001.101,33,6,0)
650	^^5^5^3110430^
651	"DATA",1130580001.101,33,6,1,0)
652	This measure assesses the number of patients who received VTE prophylaxis
653	"DATA",1130580001.101,33,6,2,0)
654	or have documentation why no VTE prophylaxis was given the day of or the
655	"DATA",1130580001.101,33,6,3,0)
656	day after the initial admission (or transfer) to the Intensive Care Unit
657	"DATA",1130580001.101,33,6,4,0)
658	(ICU) or surgery end date for surgeries that start the day of or the day
659	"DATA",1130580001.101,33,6,5,0)
660	after ICU admission (or transfer).
661	"DATA",1130580001.101,33,7)
662	NQF0372^^^^
663	"DATA",1130580001.101,34,0)
664	MU HOS NQF 0373^^
665	"DATA",1130580001.101,34,1)
666	Anticoagulation overlap therapy
667	"DATA",1130580001.101,34,5)
668	Anticoagulation overlap therapy
669	"DATA",1130580001.101,34,6,0)
670	^^8^8^3110430^
671	"DATA",1130580001.101,34,6,1,0)
672	This measure assesses the number of patients diagnosed with confirmed VTE
673	"DATA",1130580001.101,34,6,2,0)
674	who received an overlap of parenteral (intravenous [IV] or subcutaneous
675	"DATA",1130580001.101,34,6,3,0)
676	[subcu]) anticoagulation and warfarin therapy. For patients who received
677	"DATA",1130580001.101,34,6,4,0)
678	less than five days of overlap therapy, they must be discharged on both
679	"DATA",1130580001.101,34,6,5,0)
680	medications. Overlap therapy must be administered for at least five days
681	"DATA",1130580001.101,34,6,6,0)
682	with an international normalized ratio (INR) . 2 prior to discontinuation
683	"DATA",1130580001.101,34,6,7,0)
684	of the parenteral anticoagulation therapy or the patient must be
685	"DATA",1130580001.101,34,6,8,0)
686	discharged on both medications.
687	"DATA",1130580001.101,34,7)
688	NQF0373^^^^
689	"DATA",1130580001.101,35,0)
690	MU HOS NQF 0374^^
691	"DATA",1130580001.101,35,1)
692	Platelet monitoring on unfractionated heparin
693	"DATA",1130580001.101,35,5)
694	Platelet monitoring on unfractionated heparin
695	"DATA",1130580001.101,35,6,0)
696	^^10^10^3110430^
697	"DATA",1130580001.101,35,6,1,0)
698	This measure assesses the number of patients diagnosed with confirmed VTE
699	"DATA",1130580001.101,35,6,2,0)
700	who received intravenous (IV) UFH therapy dosages AND had their platelet
701	"DATA",1130580001.101,35,6,3,0)
702	counts monitored using defined parameters such as a nomogram or
703	"DATA",1130580001.101,35,6,4,0)
704	protocol This measure assesses the number of patients diagnosed with
705	"DATA",1130580001.101,35,6,5,0)
706	confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
707	"DATA",1130580001.101,35,6,6,0)
708	their platelet counts monitored using defined parameters such as a
709	"DATA",1130580001.101,35,6,7,0)
710	nomogram or protocol This measure assesses the number of patients
711	"DATA",1130580001.101,35,6,8,0)
712	diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
713	"DATA",1130580001.101,35,6,9,0)
714	dosages AND had their platelet counts monitored using defined parameters
715	"DATA",1130580001.101,35,6,10,0)
716	such as a nomogram or protocol
717	"DATA",1130580001.101,35,7)
718	NQF0374^^^^
719	"DATA",1130580001.101,36,0)
720	MU HOS NQF 0375^^
721	"DATA",1130580001.101,36,1)
722	VTE discharge instructions
723	"DATA",1130580001.101,36,5)
724	VTE discharge instructions
725	"DATA",1130580001.101,36,6,0)
726	^^11^11^3110430^
727	"DATA",1130580001.101,36,6,1,0)
728	This measure assesses the number of patients diagnosed with confirmed VTE
729	"DATA",1130580001.101,36,6,2,0)
730	that are discharged to home, to home with home health, home hospice or
731	"DATA",1130580001.101,36,6,3,0)
732	discharged/transferred to court/law enforcement on warfarin with written
733	"DATA",1130580001.101,36,6,4,0)
734	discharge instructions that address all four criteria: compliance issues,
735	"DATA",1130580001.101,36,6,5,0)
736	dietary advice, follow-up This measure assesses the number of patients
737	"DATA",1130580001.101,36,6,6,0)
738	diagnosed with confirmed VTE that are discharged to home, to home with
739	"DATA",1130580001.101,36,6,7,0)
740	home health, home hospice or discharged/transferred to court/law
741	"DATA",1130580001.101,36,6,8,0)
742	enforcement on warfarin with written discharge instructions that address
743	"DATA",1130580001.101,36,6,9,0)
744	all four criteria: compliance issues, dietary advice, follow-up
745	"DATA",1130580001.101,36,6,10,0)
746	monitoring, and information about the potential for adverse drug
747	"DATA",1130580001.101,36,6,11,0)
748	reactions/interactions.
749	"DATA",1130580001.101,36,7)
750	NQF0375^^^^
751	"DATA",1130580001.101,37,0)
752	MU HOS NQF 0376^^
753	"DATA",1130580001.101,37,1)
754	Incidence of potentially preventable VTE
755	"DATA",1130580001.101,37,5)
756	Incidence of potentially preventable VTE
757	"DATA",1130580001.101,37,6,0)
758	^^4^4^3110430^
759	"DATA",1130580001.101,37,6,1,0)
760	This measure assesses the number of patients diagnosed with confirmed VTE
761	"DATA",1130580001.101,37,6,2,0)
762	during hospitalization (not present on arrival) who did not receive VTE
763	"DATA",1130580001.101,37,6,3,0)
764	prophylaxis between hospital admission and the day before the VTE
765	"DATA",1130580001.101,37,6,4,0)
766	diagnostic testing order date.
767	"DATA",1130580001.101,37,7)
768	NQF0376^^^^
769	"DATA",1130580001.101,38,0)
770	12^^
771	"DATA",1130580001.101,38,7)
772	^^^^
773	"DATA",1130580001.101,39,0)
774	MU EP NQF 0421^^
775	"DATA",1130580001.101,39,1)
776	NQF0421 Adult Weight Screening and Follow-Up
777	"DATA",1130580001.101,39,5)
778	NQF0421 Adult Weight Screening and Follow-Up
779	"DATA",1130580001.101,39,6,0)
780	^1130580001.111^6^6^3110628^^^^
781	"DATA",1130580001.101,39,6,1,0)
782	Percentage of patients aged 18
783	"DATA",1130580001.101,39,6,2,0)
784	years and older with a calculated BMI in the past
785	"DATA",1130580001.101,39,6,3,0)
786	six months or during the current visit documented in
787	"DATA",1130580001.101,39,6,4,0)
788	the medical record AND if the most recent BMI is
789	"DATA",1130580001.101,39,6,5,0)
790	outside parameters, a follow-up plan is
791	"DATA",1130580001.101,39,6,6,0)
792	documented.
793	"DATA",1130580001.101,39,7)
794	NQF0421^^^^
795	"DATA",1130580001.101,40,0)
796	MU EP NQF 0013^^
797	"DATA",1130580001.101,40,1)
798	NQF0013 Hypertension: Blood Pressure Measurement
799	"DATA",1130580001.101,40,5)
800	NQF0013 Hypertension: Blood Pressure Measurement
801	"DATA",1130580001.101,40,6,0)
802	^1130580001.111^4^4^3120712^^^
803	"DATA",1130580001.101,40,6,1,0)
804	Percentage of patient visits for patients
805	"DATA",1130580001.101,40,6,2,0)
806	aged 18 years and older with a diagnosis of hypertension
807	"DATA",1130580001.101,40,6,3,0)
808	who have been seen for at least 2 office visits, with blood
809	"DATA",1130580001.101,40,6,4,0)
810	pressure (BP) recorded
811	"DATA",1130580001.101,40,7)
812	NQF0013^^^^^^142^167
813	"DATA",1130580001.101,41,0)
814	MU EP NQF 0028A^^
815	"DATA",1130580001.101,41,1)
816	NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
817	"DATA",1130580001.101,41,5)
818	NQF0028A Tobacco Use Assessment
819	"DATA",1130580001.101,41,6,0)
820	^1130580001.111^7^7^3110625^^^
821	"DATA",1130580001.101,41,6,1,0)
822	Percentage of patients aged 18 years and
823	"DATA",1130580001.101,41,6,2,0)
824	older who have been seen for at least 2 office visits who
825	"DATA",1130580001.101,41,6,3,0)
826	were queried about tobacco use one or more times within
827	"DATA",1130580001.101,41,6,4,0)
828	24 months b. Percentage of patients aged 18 years and
829	"DATA",1130580001.101,41,6,5,0)
830	older identified as tobacco users within the past 24
831	"DATA",1130580001.101,41,6,6,0)
832	months and have been seen for at least 2 office visits,
833	"DATA",1130580001.101,41,6,7,0)
834	who received cessation intervention.
835	"DATA",1130580001.101,41,7)
836	NQF0028A^^^^^^157^160
837	"DATA",1130580001.101,42,0)
838	MU EP NQF 0041^^
839	"DATA",1130580001.101,42,1)
840	Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old
841	"DATA",1130580001.101,42,5)
842	NQF0041 Influenza Immunization 50 years and older
843	"DATA",1130580001.101,42,6,0)
844	^^4^4^3110430^
845	"DATA",1130580001.101,42,6,1,0)
846	Percentage of patients aged 50 years
847	"DATA",1130580001.101,42,6,2,0)
848	and older who received an influenza immunization
849	"DATA",1130580001.101,42,6,3,0)
850	during the flu season (September through
851	"DATA",1130580001.101,42,6,4,0)
852	February).
853	"DATA",1130580001.101,42,7)
854	NQF0041^^^^^^242^243
855	"DATA",1130580001.101,43,0)
856	MU EP NQF 0024^^
857	"DATA",1130580001.101,43,1)
858	NQF0024 Weight Assessment and Counseling for Children and Adolescents
859	"DATA",1130580001.101,43,5)
860	NQF0024 Weight Assessment and Counseling for Children and Adolescents
861	"DATA",1130580001.101,43,6,0)
862	^1130580001.111^6^6^3120713^^
863	"DATA",1130580001.101,43,6,1,0)
864	Percentage of patients 2 -17 years of age
865	"DATA",1130580001.101,43,6,2,0)
866	who had an outpatient visit with a Primary Care Physician
867	"DATA",1130580001.101,43,6,3,0)
868	(PCP) or OB/GYN and who had evidence of BMI
869	"DATA",1130580001.101,43,6,4,0)
870	percentile documentation, counseling for nutrition and
871	"DATA",1130580001.101,43,6,5,0)
872	counseling for physical activity during the measurement
873	"DATA",1130580001.101,43,6,6,0)
874	year.
875	"DATA",1130580001.101,43,7)
876	NQF0024^^^^^^151^149
877	"DATA",1130580001.101,44,0)
878	MU EP NQF 0038^^
879	"DATA",1130580001.101,44,1)
880	Childhood Immunization Status
881	"DATA",1130580001.101,44,5)
882	Childhood Immunization Status
883	"DATA",1130580001.101,44,6,0)
884	^^14^14^3110430^
885	"DATA",1130580001.101,44,6,1,0)
886	Percentage of children 2 years of age who
887	"DATA",1130580001.101,44,6,2,0)
888	had four diphtheria, tetanus and acellular pertussis
889	"DATA",1130580001.101,44,6,3,0)
890	(DTaP); three polio(IPV), one measles, ,mumps and
891	"DATA",1130580001.101,44,6,4,0)
892	rubella (MMR); two H influenza type B (HiB); three
893	"DATA",1130580001.101,44,6,5,0)
894	Percentage of children 2 years of age who
895	"DATA",1130580001.101,44,6,6,0)
896	had four diphtheria, tetanus and acellular pertussis
897	"DATA",1130580001.101,44,6,7,0)
898	(DTaP); three polio(IPV), one measles, ,mumps and
899	"DATA",1130580001.101,44,6,8,0)
900	rubella (MMR); two H influenza type B (HiB); three
901	"DATA",1130580001.101,44,6,9,0)
902	hepatitis B (Hep B); one chicken pox (VZV); four
903	"DATA",1130580001.101,44,6,10,0)
904	pneumococcal conjugate (PCV); two hepatitis A (Hep A);
905	"DATA",1130580001.101,44,6,11,0)
906	two or three rotavirus (RV); and two influenza (flu)
907	"DATA",1130580001.101,44,6,12,0)
908	vaccines by their second birthday. The measure
909	"DATA",1130580001.101,44,6,13,0)
910	calculates a rate for each vaccine and nine separate
911	"DATA",1130580001.101,44,6,14,0)
912	combination rates.
913	"DATA",1130580001.101,44,7)
914	NQF0038^^^^
915	"DATA",1130580001.101,45,0)
916	MU EP NQF 0059^^
917	"DATA",1130580001.101,45,1)
918	Diabetes: Hemoglobin A1c Poor Contro
919	"DATA",1130580001.101,45,5)
920	Diabetes: NQF0059 Hemoglobin A1c Poor Control
921	"DATA",1130580001.101,45,6,0)
922	^^2^2^3110430^
923	"DATA",1130580001.101,45,6,1,0)
924	Percentage of patients 18 - 75 years of age with diabetes (type 1
925	"DATA",1130580001.101,45,6,2,0)
926	or type 2) who had hemoglobin A1c > 9.0%.
927	"DATA",1130580001.101,45,7)
928	NQF0059^^^^
929	"DATA",1130580001.101,46,0)
930	MU EP NQF 0064^^
931	"DATA",1130580001.101,46,1)
932	Diabetes: Low Density Lipoprotein (LDL) Management and Control
933	"DATA",1130580001.101,46,5)
934	NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control
935	"DATA",1130580001.101,46,6,0)
936	^^3^3^3110430^
937	"DATA",1130580001.101,46,6,1,0)
938	Percentage of patients 18-75 years of age with diabetes (type 1
939	"DATA",1130580001.101,46,6,2,0)
940	or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years
941	"DATA",1130580001.101,46,6,3,0)
942	of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
943	"DATA",1130580001.101,46,7)
944	NQF0064^^^^
945	"DATA",1130580001.101,47,0)
946	MU EP NQF 0061^^
947	"DATA",1130580001.101,47,1)
948	Blood Pressure Management
949	"DATA",1130580001.101,47,5)
950	NQF0061 Diabetes: Blood Pressure Management
951	"DATA",1130580001.101,47,6,0)
952	^^2^2^3110430^
953	"DATA",1130580001.101,47,6,1,0)
954	Percentage of patients 18 - 75 years of age with
955	"DATA",1130580001.101,47,6,2,0)
956	diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
957	"DATA",1130580001.101,47,7)
958	NQF0061^^^^
959	"DATA",1130580001.101,48,0)
960	MU EP NQF 0081^^
961	"DATA",1130580001.101,48,1)
962	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
963	"DATA",1130580001.101,48,5)
964	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
965	"DATA",1130580001.101,48,6,0)
966	^^3^3^3110430^
967	"DATA",1130580001.101,48,6,1,0)
968	Percentage of patients aged 18 years and older with a
969	"DATA",1130580001.101,48,6,2,0)
970	diagnosis of heart failure and LVSD (LVEF < 40%) who were
971	"DATA",1130580001.101,48,6,3,0)
972	prescribed ACE inhibitor or ARB therapy
973	"DATA",1130580001.101,48,7)
974	NQF0081^^^^
975	"DATA",1130580001.101,49,0)
976	MU EP NQF 0070^^
977	"DATA",1130580001.101,49,1)
978	Pneumonia Vaccination Status for Older Adults
979	"DATA",1130580001.101,49,5)
980	Pneumonia Vaccination Status for Older Adults
981	"DATA",1130580001.101,49,6,0)
982	^^2^2^3110430^
983	"DATA",1130580001.101,49,6,1,0)
984	Percentage of patients 65 years of age and older who have ever
985	"DATA",1130580001.101,49,6,2,0)
986	received a pneumococcal vaccine.
987	"DATA",1130580001.101,49,7)
988	NQF0070^^^^
989	"DATA",1130580001.101,50,0)
990	MU EP NQF 0031^^
991	"DATA",1130580001.101,50,1)
992	Breast Cancer Screening
993	"DATA",1130580001.101,50,5)
994	Breast Cancer Screening
995	"DATA",1130580001.101,50,6,0)
996	^^2^2^3110430^
997	"DATA",1130580001.101,50,6,1,0)
998	Percentage of women 40-69 years of age who had a
999	"DATA",1130580001.101,50,6,2,0)
1000	mammogram to screen for breast cancer
1001	"DATA",1130580001.101,50,7)
1002	NQF0031^^^^
1003	"DATA",1130580001.101,51,0)
1004	MU EP NQF 0034^^
1005	"DATA",1130580001.101,51,1)
1006	Colorectal Cancer Screening
1007	"DATA",1130580001.101,51,5)
1008	Colorectal Cancer Screening
1009	"DATA",1130580001.101,51,6,0)
1010	^^2^2^3110430^
1011	"DATA",1130580001.101,51,6,1,0)
1012	Percentage of adults 50-75 years of age who had appropriate screening for
1013	"DATA",1130580001.101,51,6,2,0)
1014	colorectal cancer.
1015	"DATA",1130580001.101,51,7)
1016	NQF0034^^^^
1017	"DATA",1130580001.101,52,0)
1018	MU EP NQF 0067^^
1019	"DATA",1130580001.101,52,1)
1020	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1021	"DATA",1130580001.101,52,5)
1022	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1023	"DATA",1130580001.101,52,6,0)
1024	^^2^2^3110430^
1025	"DATA",1130580001.101,52,6,1,0)
1026	Percentage of patients aged 18 years and older with a
1027	"DATA",1130580001.101,52,6,2,0)
1028	diagnosis of CAD who were prescribed oral antiplatelet therapy.
1029	"DATA",1130580001.101,52,7)
1030	NQF0067^^^^
1031	"DATA",1130580001.101,53,0)
1032	MU EP NQF 0083^^
1033	"DATA",1130580001.101,53,1)
1034	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1035	"DATA",1130580001.101,53,5)
1036	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1037	"DATA",1130580001.101,53,6,0)
1038	^^3^3^3110430^
1039	"DATA",1130580001.101,53,6,1,0)
1040	Percentage of patients aged 18 years and older with a
1041	"DATA",1130580001.101,53,6,2,0)
1042	diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were
1043	"DATA",1130580001.101,53,6,3,0)
1044	prescribed beta-blocker therapy
1045	"DATA",1130580001.101,53,7)
1046	NQF0083^^^^
1047	"DATA",1130580001.101,54,0)
1048	MU EP NQF 0105^^
1049	"DATA",1130580001.101,54,1)
1050	Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1051	"DATA",1130580001.101,54,5)
1052	Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1053	"DATA",1130580001.101,54,6,0)
1054	^^4^4^3110430^
1055	"DATA",1130580001.101,54,6,1,0)
1056	The percentage of patients 18 years of age and older
1057	"DATA",1130580001.101,54,6,2,0)
1058	who were diagnosed with a new episode of major depression, treated
1059	"DATA",1130580001.101,54,6,3,0)
1060	with antidepressant medication, and who remained on an
1061	"DATA",1130580001.101,54,6,4,0)
1062	antidepressant medication treatment.
1063	"DATA",1130580001.101,54,7)
1064	NQF0105^^^^
1065	"DATA",1130580001.101,55,0)
1066	MU EP NQF 0086^^
1067	"DATA",1130580001.101,55,1)
1068	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1069	"DATA",1130580001.101,55,5)
1070	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1071	"DATA",1130580001.101,55,6,0)
1072	^^4^4^3110430^
1073	"DATA",1130580001.101,55,6,1,0)
1074	Percentage of patients aged 18 years and older with a
1075	"DATA",1130580001.101,55,6,2,0)
1076	diagnosis of POAG who have been seen for at least two office visits
1077	"DATA",1130580001.101,55,6,3,0)
1078	who have an optic nerve head evaluation during one or more office
1079	"DATA",1130580001.101,55,6,4,0)
1080	visits within 12 months.
1081	"DATA",1130580001.101,55,7)
1082	NQF0086^^^^
1083	"DATA",1130580001.101,56,0)
1084	MU EP NQF 0088^^
1085	"DATA",1130580001.101,56,1)
1086	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1087	"DATA",1130580001.101,56,5)
1088	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1089	"DATA",1130580001.101,56,6,0)
1090	^^5^5^3110430^
1091	"DATA",1130580001.101,56,6,1,0)
1092	Percentage of patients aged 18 years and older with a
1093	"DATA",1130580001.101,56,6,2,0)
1094	diagnosis of diabetic retinopathy who had a dilated macular or fundus
1095	"DATA",1130580001.101,56,6,3,0)
1096	exam performed which included documentation of the level of severity
1097	"DATA",1130580001.101,56,6,4,0)
1098	of retinopathy and the presence or absence of macular edema during
1099	"DATA",1130580001.101,56,6,5,0)
1100	one or more office visits within 12 months.
1101	"DATA",1130580001.101,56,7)
1102	NQF0088^^^^
1103	"DATA",1130580001.101,57,0)
1104	MU EP NQF 0089^^
1105	"DATA",1130580001.101,57,1)
1106	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1107	"DATA",1130580001.101,57,5)
1108	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1109	"DATA",1130580001.101,57,6,0)
1110	^^6^6^3110430^
1111	"DATA",1130580001.101,57,6,1,0)
1112	Percentage of patients aged 18 years and older with a
1113	"DATA",1130580001.101,57,6,2,0)
1114	diagnosis of diabetic retinopathy who had a dilated macular or fundus
1115	"DATA",1130580001.101,57,6,3,0)
1116	exam performed with documented communication to the physician who
1117	"DATA",1130580001.101,57,6,4,0)
1118	manages the ongoing care of the patient with diabetes mellitus
1119	"DATA",1130580001.101,57,6,5,0)
1120	regarding the findings of the macular or fundus exam at least once
1121	"DATA",1130580001.101,57,6,6,0)
1122	within 12 months.
1123	"DATA",1130580001.101,57,7)
1124	NQF0089^^^^
1125	"DATA",1130580001.101,58,0)
1126	MU EP NQF 0047^^
1127	"DATA",1130580001.101,58,1)
1128	Asthma Pharmacologic Therapy
1129	"DATA",1130580001.101,58,5)
1130	Asthma Pharmacologic Therapy
1131	"DATA",1130580001.101,58,6,0)
1132	^1130580001.111^4^4^3110430^^
1133	"DATA",1130580001.101,58,6,1,0)
1134	Percentage of patients aged 5 through 40 years with a
1135	"DATA",1130580001.101,58,6,2,0)
1136	diagnosis of mild, moderate, or severe persistent asthma who were
1137	"DATA",1130580001.101,58,6,3,0)
1138	prescribed either the preferred long-term control medication (inhaled
1139	"DATA",1130580001.101,58,6,4,0)
1140	corticosteroid) or an acceptable alternative treatment
1141	"DATA",1130580001.101,58,7)
1142	NQF0047^^^^
1143	"DATA",1130580001.101,59,0)
1144	MU EP NQF 0001^^
1145	"DATA",1130580001.101,59,1)
1146	Asthma Assessment
1147	"DATA",1130580001.101,59,5)
1148	Asthma Assessment
1149	"DATA",1130580001.101,59,6,0)
1150	^^5^5^3110430^
1151	"DATA",1130580001.101,59,6,1,0)
1152	Percentage of patients aged 5 through 40 years with a
1153	"DATA",1130580001.101,59,6,2,0)
1154	diagnosis of asthma and who have been seen for at least 2 office
1155	"DATA",1130580001.101,59,6,3,0)
1156	visits, who were evaluated during at least one office visit within 12
1157	"DATA",1130580001.101,59,6,4,0)
1158	months for the frequency (numeric) of daytime and nocturnal asthma
1159	"DATA",1130580001.101,59,6,5,0)
1160	symptoms.
1161	"DATA",1130580001.101,59,7)
1162	NQF0001^^^^
1163	"DATA",1130580001.101,60,0)
1164	MU EP NQF 0002^^
1165	"DATA",1130580001.101,60,1)
1166	Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer
1167	"DATA",1130580001.101,60,5)
1168	Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
1169	"DATA",1130580001.101,60,6,0)
1170	^^4^4^3110430^
1171	"DATA",1130580001.101,60,6,1,0)
1172	Percentage of female patients aged 18 years and older
1173	"DATA",1130580001.101,60,6,2,0)
1174	with Stage IC through IIIC, ER or PR positive breast cancer who were
1175	"DATA",1130580001.101,60,6,3,0)
1176	prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month
1177	"DATA",1130580001.101,60,6,4,0)
1178	reporting period.
1179	"DATA",1130580001.101,60,7)
1180	NQF0002^^^^
1181	"DATA",1130580001.101,61,0)
1182	MU EP NQF 0385^^
1183	"DATA",1130580001.101,61,1)
1184	Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1185	"DATA",1130580001.101,61,5)
1186	Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1187	"DATA",1130580001.101,61,6,0)
1188	^^4^4^3110430^
1189	"DATA",1130580001.101,61,6,1,0)
1190	Percentage of patients aged 18 years and older with
1191	"DATA",1130580001.101,61,6,2,0)
1192	Stage IIIA through IIIC colon cancer who are referred for adjuvant
1193	"DATA",1130580001.101,61,6,3,0)
1194	chemotherapy, prescribed adjuvant chemotherapy, or have previously
1195	"DATA",1130580001.101,61,6,4,0)
1196	received adjuvant chemotherapy within the 12-month reporting period
1197	"DATA",1130580001.101,61,7)
1198	NQF0385^^^^
1199	"DATA",1130580001.101,62,0)
1200	MU EP NQF 0389^^
1201	"DATA",1130580001.101,62,1)
1202	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1203	"DATA",1130580001.101,62,5)
1204	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1205	"DATA",1130580001.101,62,6,0)
1206	^^5^5^3110430^
1207	"DATA",1130580001.101,62,6,1,0)
1208	Percentage of patients, regardless of age, with a diagnosis of
1209	"DATA",1130580001.101,62,6,2,0)
1210	prostate cancer at low risk of recurrence receiving interstitial prostate
1211	"DATA",1130580001.101,62,6,3,0)
1212	brachytherapy, OR external beam radiotherapy to the prostate, OR radical
1213	"DATA",1130580001.101,62,6,4,0)
1214	prostatectomy, OR cryotherapy who did not have a bone scan performed at
1215	"DATA",1130580001.101,62,6,5,0)
1216	any time since diagnosis of prostate cancer.
1217	"DATA",1130580001.101,62,7)
1218	NQF0389^^^^
1219	"DATA",1130580001.101,63,0)
1220	MU EP NQF 0027^^
1221	"DATA",1130580001.101,63,1)
1222	Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising
1223	"DATA",1130580001.101,63,5)
1224	Smoking and Tobacco Use Cessation
1225	"DATA",1130580001.101,63,6,0)
1226	^^5^5^3110430^
1227	"DATA",1130580001.101,63,6,1,0)
1228	Percentage of patients 18 years of age and older who were
1229	"DATA",1130580001.101,63,6,2,0)
1230	current smokers or tobacco users, who were seen by a practitioner during
1231	"DATA",1130580001.101,63,6,3,0)
1232	the measurement year and who received advice to quit smoking or tobacco
1233	"DATA",1130580001.101,63,6,4,0)
1234	use or whose practitioner recommended or discussed smoking or tobacco use
1235	"DATA",1130580001.101,63,6,5,0)
1236	cessation medications, methods or strategies
1237	"DATA",1130580001.101,63,7)
1238	NQF0027^^^^
1239	"DATA",1130580001.101,64,0)
1240	MU EP NQF 0055^^
1241	"DATA",1130580001.101,64,1)
1242	Diabetes: Eye Exam
1243	"DATA",1130580001.101,64,5)
1244	Diabetes: Eye Exam
1245	"DATA",1130580001.101,64,6,0)
1246	^^3^3^3110430^
1247	"DATA",1130580001.101,64,6,1,0)
1248	Percentage of patients 18 -75 years of age with diabetes (type 1
1249	"DATA",1130580001.101,64,6,2,0)
1250	or type 2) who had a retinal or dilated eye exam or a negative retinal
1251	"DATA",1130580001.101,64,6,3,0)
1252	exam (no evidence of retinopathy) by an eye care professional
1253	"DATA",1130580001.101,64,7)
1254	NQF0055^^^^
1255	"DATA",1130580001.101,65,0)
1256	MU EP NQF 0062^^
1257	"DATA",1130580001.101,65,1)
1258	Diabetes: Urine Screening
1259	"DATA",1130580001.101,65,5)
1260	Diabetes: Urine Screening
1261	"DATA",1130580001.101,65,6,0)
1262	^^3^3^3110430^
1263	"DATA",1130580001.101,65,6,1,0)
1264	Percentage of patients 18 - 75 years of age with diabetes (type 1
1265	"DATA",1130580001.101,65,6,2,0)
1266	or type 2) who had a nephropathy screening test or evidence of
1267	"DATA",1130580001.101,65,6,3,0)
1268	nephropathy.
1269	"DATA",1130580001.101,65,7)
1270	NQF0062^^^^
1271	"DATA",1130580001.101,66,0)
1272	MU EP NQF 0056^^
1273	"DATA",1130580001.101,66,1)
1274	Diabetes: Foot Exam
1275	"DATA",1130580001.101,66,5)
1276	Diabetes: Foot Exam
1277	"DATA",1130580001.101,66,6,0)
1278	^^3^3^3110430^
1279	"DATA",1130580001.101,66,6,1,0)
1280	The percentage of patients aged 18 - 75 years with diabetes
1281	"DATA",1130580001.101,66,6,2,0)
1282	(type 1 or type 2) who had a foot exam (visual inspection, sensory exam
1283	"DATA",1130580001.101,66,6,3,0)
1284	with monofilament, or pulse exam).
1285	"DATA",1130580001.101,66,7)
1286	NQF0056^^^^
1287	"DATA",1130580001.101,67,0)
1288	MU EP NQF 0074^^
1289	"DATA",1130580001.101,67,1)
1290	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1291	"DATA",1130580001.101,67,5)
1292	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1293	"DATA",1130580001.101,67,6,0)
1294	^^3^3^3110430^
1295	"DATA",1130580001.101,67,6,1,0)
1296	Percentage of patients aged 18 years and older with a
1297	"DATA",1130580001.101,67,6,2,0)
1298	diagnosis of CAD who were prescribed a lipid-lowering therapy (based
1299	"DATA",1130580001.101,67,6,3,0)
1300	on current ACC/AHA guidelines).
1301	"DATA",1130580001.101,67,7)
1302	NQF0074^^^^
1303	"DATA",1130580001.101,68,0)
1304	MU EP NQF 0084^^
1305	"DATA",1130580001.101,68,1)
1306	Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1307	"DATA",1130580001.101,68,5)
1308	Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1309	"DATA",1130580001.101,68,6,0)
1310	^^3^3^3110430^
1311	"DATA",1130580001.101,68,6,1,0)
1312	Percentage of all patients aged 18 years and older with a
1313	"DATA",1130580001.101,68,6,2,0)
1314	diagnosis of heart failure and paroxysmal or chronic atrial fibrillation
1315	"DATA",1130580001.101,68,6,3,0)
1316	who were prescribed warfarin therapy.
1317	"DATA",1130580001.101,68,7)
1318	NQF0084^^^^
1319	"DATA",1130580001.101,69,0)
1320	MU EP NQF 0073^^
1321	"DATA",1130580001.101,69,1)
1322	Ischemic Vascular Disease (IVD): Blood Pressure Management
1323	"DATA",1130580001.101,69,5)
1324	Ischemic Vascular Disease (IVD): Blood Pressure Management
1325	"DATA",1130580001.101,69,6,0)
1326	^^11^11^3110430^
1327	"DATA",1130580001.101,69,6,1,0)
1328	Percentage of patients 18 years of age and older who
1329	"DATA",1130580001.101,69,6,2,0)
1330	were discharged alive for acute myocardial infarction (AMI), coronary
1331	"DATA",1130580001.101,69,6,3,0)
1332	artery bypass graft (CABG) or percutaneous transluminal coronary
1333	"DATA",1130580001.101,69,6,4,0)
1334	Percentage of patients 18 years of age and older who
1335	"DATA",1130580001.101,69,6,5,0)
1336	were discharged alive for acute myocardial infarction (AMI), coronary
1337	"DATA",1130580001.101,69,6,6,0)
1338	artery bypass graft (CABG) or percutaneous transluminal coronary
1339	"DATA",1130580001.101,69,6,7,0)
1340	angioplasty (PTCA) from January 1- November 1 of the year prior to
1341	"DATA",1130580001.101,69,6,8,0)
1342	the measurement year, or who had a diagnosis of ischemic vascular
1343	"DATA",1130580001.101,69,6,9,0)
1344	disease (IVD) during the measurement year and the year prior to the
1345	"DATA",1130580001.101,69,6,10,0)
1346	measurement year and whose recent blood pressure is in control
1347	"DATA",1130580001.101,69,6,11,0)
1348	(<140/90 mmHg).
1349	"DATA",1130580001.101,69,7)
1350	NQF0073^^^^
1351	"DATA",1130580001.101,70,0)
1352	MU EP NQF 0068^^
1353	"DATA",1130580001.101,70,1)
1354	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1355	"DATA",1130580001.101,70,5)
1356	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1357	"DATA",1130580001.101,70,6,0)
1358	^^8^8^3110430^
1359	"DATA",1130580001.101,70,6,1,0)
1360	Percentage of patients 18 years of age and older who were
1361	"DATA",1130580001.101,70,6,2,0)
1362	discharged alive for acute myocardial infarction (AMI), coronary artery
1363	"DATA",1130580001.101,70,6,3,0)
1364	bypass graft (CABG) or percutaneous transluminal coronary
1365	"DATA",1130580001.101,70,6,4,0)
1366	angioplasty (PTCA) from January 1-November 1 of the year prior to the
1367	"DATA",1130580001.101,70,6,5,0)
1368	measurement year, or who had a diagnosis of ischemic vascular
1369	"DATA",1130580001.101,70,6,6,0)
1370	disease (IVD) during the measurement year and the year prior to the
1371	"DATA",1130580001.101,70,6,7,0)
1372	measurement year and who had documentation of use of aspirin or
1373	"DATA",1130580001.101,70,6,8,0)
1374	another antithrombotic during the measurement year
1375	"DATA",1130580001.101,70,7)
1376	NQF0068^^^^
1377	"DATA",1130580001.101,71,0)
1378	MU EP NQF 0004^^
1379	"DATA",1130580001.101,71,1)
1380	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement
1381	"DATA",1130580001.101,71,5)
1382	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a) Initiation,(b) Engagement
1383	"DATA",1130580001.101,71,6,0)
1384	^^6^6^3110430^
1385	"DATA",1130580001.101,71,6,1,0)
1386	The percentage of adolescent and adult patients with a new
1387	"DATA",1130580001.101,71,6,2,0)
1388	episode of alcohol and other drug (AOD) dependence who initiate treatment
1389	"DATA",1130580001.101,71,6,3,0)
1390	through an inpatient AOD admission, outpatient visit, intensive
1391	"DATA",1130580001.101,71,6,4,0)
1392	outpatient encounter or partial hospitalization within 14 days of the
1393	"DATA",1130580001.101,71,6,5,0)
1394	diagnosis and who initiated treatment and who had two or more additional
1395	"DATA",1130580001.101,71,6,6,0)
1396	services with an AOD diagnosis within 30 days of the initiation visit.
1397	"DATA",1130580001.101,71,7)
1398	NQF0004^^^^
1399	"DATA",1130580001.101,72,0)
1400	MU EP NQF 0012^^
1401	"DATA",1130580001.101,72,1)
1402	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1403	"DATA",1130580001.101,72,5)
1404	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1405	"DATA",1130580001.101,72,6,0)
1406	^^3^3^3110430^
1407	"DATA",1130580001.101,72,6,1,0)
1408	Percentage of patients, regardless of age, who gave birth during
1409	"DATA",1130580001.101,72,6,2,0)
1410	a 12-month period who were screened for HIV infection during the first or
1411	"DATA",1130580001.101,72,6,3,0)
1412	second prenatal care visit.
1413	"DATA",1130580001.101,72,7)
1414	NQF0012^^^^
1415	"DATA",1130580001.101,73,0)
1416	MU EP NQF 0014^^
1417	"DATA",1130580001.101,73,1)
1418	Prenatal Care: Anti-D Immune Globulin
1419	"DATA",1130580001.101,73,5)
1420	Prenatal Care: Anti-D Immune Globulin
1421	"DATA",1130580001.101,73,6,0)
1422	^^3^3^3110430^
1423	"DATA",1130580001.101,73,6,1,0)
1424	Percentage of D (Rh) negative, unsensitized patients, regardless
1425	"DATA",1130580001.101,73,6,2,0)
1426	of age, who gave birth during a 12-month period who received anti-D
1427	"DATA",1130580001.101,73,6,3,0)
1428	immune globulin at 26-30 weeks gestation.
1429	"DATA",1130580001.101,73,7)
1430	NQD0014^^^^
1431	"DATA",1130580001.101,74,0)
1432	MU EP NQF 0018^^
1433	"DATA",1130580001.101,74,1)
1434	Controlling High Blood Pressure
1435	"DATA",1130580001.101,74,5)
1436	Controlling High Blood Pressure
1437	"DATA",1130580001.101,74,6,0)
1438	^^3^3^3110430^
1439	"DATA",1130580001.101,74,6,1,0)
1440	The percentage of patients 18-85 years of age who had a
1441	"DATA",1130580001.101,74,6,2,0)
1442	diagnosis of hypertension and whose BP was adequately controlled during
1443	"DATA",1130580001.101,74,6,3,0)
1444	the measurement year
1445	"DATA",1130580001.101,74,7)
1446	NQF0018^^^^
1447	"DATA",1130580001.101,75,0)
1448	MU EP NQF 0032^^
1449	"DATA",1130580001.101,75,1)
1450	Cervical Cancer Screening
1451	"DATA",1130580001.101,75,5)
1452	Cervical Cancer Screening
1453	"DATA",1130580001.101,75,6,0)
1454	^^2^2^3110430^
1455	"DATA",1130580001.101,75,6,1,0)
1456	Percentage of women 21-64 years of age, who received one or
1457	"DATA",1130580001.101,75,6,2,0)
1458	more Pap tests to screen for cervical cancer
1459	"DATA",1130580001.101,75,7)
1460	NQF0032^^^^
1461	"DATA",1130580001.101,76,0)
1462	MU EP NQF 0033^^
1463	"DATA",1130580001.101,76,1)
1464	Chlamydia Screening for Women
1465	"DATA",1130580001.101,76,5)
1466	Chlamydia Screening for Women
1467	"DATA",1130580001.101,76,6,0)
1468	^^3^3^3110430^
1469	"DATA",1130580001.101,76,6,1,0)
1470	Percentage of women 15- 24 years of age who were identified as sexually
1471	"DATA",1130580001.101,76,6,2,0)
1472	active and who had at least one test for chlamydia during the measurement
1473	"DATA",1130580001.101,76,6,3,0)
1474	year.
1475	"DATA",1130580001.101,76,7)
1476	NQF0033^^^^
1477	"DATA",1130580001.101,77,0)
1478	MU EP NQF 0036^^
1479	"DATA",1130580001.101,77,1)
1480	Use of Appropriate Medications for Asthma
1481	"DATA",1130580001.101,77,5)
1482	Use of Appropriate Medications for Asthma
1483	"DATA",1130580001.101,77,6,0)
1484	^^4^4^3110430^
1485	"DATA",1130580001.101,77,6,1,0)
1486	Percentage of patients 5 - 50 years of age who were identified as having
1487	"DATA",1130580001.101,77,6,2,0)
1488	persistent asthma and were appropriately prescribed medication during the
1489	"DATA",1130580001.101,77,6,3,0)
1490	measurement year. Report three age stratifications (5-11 years, 12-50
1491	"DATA",1130580001.101,77,6,4,0)
1492	years, and total).
1493	"DATA",1130580001.101,77,7)
1494	NQF0036^^^^
1495	"DATA",1130580001.101,78,0)
1496	MU EP NQF 0052^^
1497	"DATA",1130580001.101,78,1)
1498	Low Back Pain: Use of Imaging Studies
1499	"DATA",1130580001.101,78,5)
1500	Low Back Pain: Use of Imaging Studies
1501	"DATA",1130580001.101,78,6,0)
1502	^1130580001.111^3^3^3110430^^
1503	"DATA",1130580001.101,78,6,1,0)
1504	Percentage of patients with a primary diagnosis of low back pain
1505	"DATA",1130580001.101,78,6,2,0)
1506	who did not have an imaging study (plain x-ray, MRI, CT scan) within 28
1507	"DATA",1130580001.101,78,6,3,0)
1508	days of diagnosis.
1509	"DATA",1130580001.101,78,7)
1510	NQF0052^^^^
1511	"DATA",1130580001.101,79,0)
1512	MU EP NQF 0075^^
1513	"DATA",1130580001.101,79,1)
1514	Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1515	"DATA",1130580001.101,79,5)
1516	Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1517	"DATA",1130580001.101,79,6,0)
1518	^^7^7^3110430^
1519	"DATA",1130580001.101,79,6,1,0)
1520	Percentage of patients 18 years of age and older who were discharged alive
1521	"DATA",1130580001.101,79,6,2,0)
1522	for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
1523	"DATA",1130580001.101,79,6,3,0)
1524	or percutaneous transluminal angioplasty (PTCA) from January 1-November1
1525	"DATA",1130580001.101,79,6,4,0)
1526	of the year prior to the measurement year, or who had a diagnosis of
1527	"DATA",1130580001.101,79,6,5,0)
1528	ischemic vascular disease (IVD) during the measurement year and the year
1529	"DATA",1130580001.101,79,6,6,0)
1530	prior to the measurement year and who had a complete lipid profile
1531	"DATA",1130580001.101,79,6,7,0)
1532	performed during the measurement year and whose LDL-C<100 mg/dL
1533	"DATA",1130580001.101,79,7)
1534	NQF0075^^^^
1535	"DATA",1130580001.101,80,0)
1536	MU EP NQF 0575^^
1537	"DATA",1130580001.101,80,1)
1538	Diabetes: Hemoglobin A1c Control (<8.0%)
1539	"DATA",1130580001.101,80,5)
1540	Diabetes: Hemoglobin A1c Control (<8.0%)
1541	"DATA",1130580001.101,80,6,0)
1542	^^2^2^3110430^
1543	"DATA",1130580001.101,80,6,1,0)
1544	The percentage of patients 18-75 years of age with diabetes
1545	"DATA",1130580001.101,80,6,2,0)
1546	(type 1 or type 2) who had hemoglobin A1c <8.0%
1547	"DATA",1130580001.101,80,7)
1548	NQF0575^^^^
1549	"DATA",1130580001.101,81,0)
1550	MU EP NQF 0028B^^
1551	"DATA",1130580001.101,81,1)
1552	NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
1553	"DATA",1130580001.101,81,5)
1554	NQF0028B Tobacco Use Assessment and Cessation Intervention
1555	"DATA",1130580001.101,81,6,0)
1556	^1130580001.111^7^7^3110625^^^^
1557	"DATA",1130580001.101,81,6,1,0)
1558	Percentage of patients aged 18 years and
1559	"DATA",1130580001.101,81,6,2,0)
1560	older who have been seen for at least 2 office visits who
1561	"DATA",1130580001.101,81,6,3,0)
1562	were queried about tobacco use one or more times within
1563	"DATA",1130580001.101,81,6,4,0)
1564	24 months b. Percentage of patients aged 18 years and
1565	"DATA",1130580001.101,81,6,5,0)
1566	older identified as tobacco users within the past 24
1567	"DATA",1130580001.101,81,6,6,0)
1568	months and have been seen for at least 2 office visits,
1569	"DATA",1130580001.101,81,6,7,0)
1570	who received cessation intervention.
1571	"DATA",1130580001.101,81,7)
1572	NQF0028B^^^^^^154^160
1573	"DATA",1130580001.101,82,0)
1574	MU EP 0028B^^
1575	"DATA",1130580001.101,82,7)
1576	^^^^
1577	"DATA",1130580001.101,83,0)
1578	NQF0038 NUM1 DPT^^
1579	"DATA",1130580001.101,83,5)
1580	NQF0038 NUM1 DPT
1581	"DATA",1130580001.101,83,7)
1582	NQF0038 NUM1 DPT^^^^
1583	"DATA",1130580001.101,84,0)
1584	NQF0038 NUM2 IPV^^
1585	"DATA",1130580001.101,84,5)
1586	NQF0038 NUM2 IPV
1587	"DATA",1130580001.101,84,7)
1588	NQF0038 NUM2 IPV^^^^
1589	"DATA",1130580001.101,85,0)
1590	NQF0038 NUM3 MMR^^
1591	"DATA",1130580001.101,85,5)
1592	NQF0038 NUM3 MMR
1593	"DATA",1130580001.101,85,7)
1594	NQF0038 NUM3 MMR^^^^
1595	"DATA",1130580001.101,86,0)
1596	NQF0038 NUM4 HiB^^
1597	"DATA",1130580001.101,86,5)
1598	NQF0038 NUM4 HiB
1599	"DATA",1130580001.101,86,7)
1600	NQF0038 NUM4 HiB^^^^
1601	"DATA",1130580001.101,87,0)
1602	NQF0038 NUM5 HEP B^^
1603	"DATA",1130580001.101,87,5)
1604	NQF0038 NUM5 HEP B
1605	"DATA",1130580001.101,87,7)
1606	NQF0038 NUM5 HEP B^^^^
1607	"DATA",1130580001.101,88,0)
1608	NQF0038 NUM6 VZV^^
1609	"DATA",1130580001.101,88,5)
1610	NQF0038 NUM6 VZV
1611	"DATA",1130580001.101,88,7)
1612	NQF0038 NUM6 VZV^^^^
1613	"DATA",1130580001.101,89,0)
1614	NQF0038 NUM7 PCV^^
1615	"DATA",1130580001.101,89,5)
1616	NQF0038 NUM7 PCV
1617	"DATA",1130580001.101,89,7)
1618	NQF0038 NUM7 PCV^^^^
1619	"DATA",1130580001.101,90,0)
1620	NQF0038 NUM8 HEP A^^
1621	"DATA",1130580001.101,90,5)
1622	NQF0038 NUM8 HEP A
1623	"DATA",1130580001.101,90,7)
1624	NQF0038 NUM8 HEP A^^^^
1625	"DATA",1130580001.101,91,0)
1626	NQF0038 NUM9^^
1627	"DATA",1130580001.101,91,5)
1628	NQF0038 NUM9
1629	"DATA",1130580001.101,91,7)
1630	NQF0038 NUM9^^^^
1631	"DATA",1130580001.101,92,0)
1632	NQF0038 NUM10^^
1633	"DATA",1130580001.101,92,5)
1634	NQF0038 NUM10
1635	"DATA",1130580001.101,92,7)
1636	NQF0038 NUM10^^^^
1637	"DATA",1130580001.101,93,0)
1638	NQF0038 NUM11 COMBO5^^
1639	"DATA",1130580001.101,93,5)
1640	NQF0038 NUM11 COMBO5
1641	"DATA",1130580001.101,93,7)
1642	NQF0038 NUM11 COMBO5^^^^
1643	"DATA",1130580001.101,94,0)
1644	NQF0038 NUM12 COMBO6^^
1645	"DATA",1130580001.101,94,5)
1646	NQF0038 NUM12 COMBO6
1647	"DATA",1130580001.101,94,7)
1648	NQF0038 NUM12 COMBO6^^^^
1649	"DATA",1130580001.101,95,0)
1650	MU 2011 INP ADV DIRECTIVES^^
1651	"DATA",1130580001.101,95,5)
1652	Advance Directives
1653	"DATA",1130580001.101,95,7)
1654	^^^^
1655	"DATA",1130580001.101,96,0)
1656	MU 2011 INP CPOE^^
1657	"DATA",1130580001.101,96,5)
1658	CPOE for Medications
1659	"DATA",1130580001.101,96,7)
1660	^^^^
1661	"DATA",1130580001.101,97,0)
1662	MU 2011 INP MED RECON^^
1663	"DATA",1130580001.101,97,5)
1664	Medication Reconcilliation
1665	"DATA",1130580001.101,97,7)
1666	^^^^
1667	"DATA",1130580001.101,98,0)
1668	MU 2011 INP PROBLEM LIST^^
1669	"DATA",1130580001.101,98,5)
1670	Problem List
1671	"DATA",1130580001.101,98,7)
1672	^^^^
1673	"DATA",1130580001.101,99,0)
1674	MU 2011 INP VITAL SIGNS^^
1675	"DATA",1130580001.101,99,5)
1676	Record Vital Signs
1677	"DATA",1130580001.101,99,7)
1678	^^^^
1679	"DATA",1130580001.101,100,0)
1680	MU 2011 INP SMOKING STATUS^^
1681	"DATA",1130580001.101,100,5)
1682	Smoking Status
1683	"DATA",1130580001.101,100,7)
1684	^^^^
1685	"DATA",1130580001.101,101,0)
1686	MU 2011 INP MED LIST^^
1687	"DATA",1130580001.101,101,5)
1688	Active Medication List
1689	"DATA",1130580001.101,101,7)
1690	^^^^
1691	"DATA",1130580001.101,102,0)
1692	MU 2011 INP ALLERGY LIST^^
1693	"DATA",1130580001.101,102,5)
1694	Medication Allergy List
1695	"DATA",1130580001.101,102,7)
1696	^^^^
1697	"DATA",1130580001.101,103,0)
1698	MU 2011 INP DEMOGRAPHICS^^
1699	"DATA",1130580001.101,103,5)
1700	Record Demographics
1701	"DATA",1130580001.101,103,7)
1702	^^^^
1703	"FIA",1130580001.101)
1704	C0Q QUALITY MEASURE
1705	"FIA",1130580001.101,0)
1706	^C0Q(101,
1707	"FIA",1130580001.101,0,0)
1708	1130580001.101I
1709	"FIA",1130580001.101,0,1)
1710	y^y^f^^y^^y^o^n
1711	"FIA",1130580001.101,0,10)
1712
1713	"FIA",1130580001.101,0,11)
1714
1715	"FIA",1130580001.101,0,"RLRO")
1716
1717	"FIA",1130580001.101,0,"VR")
1718	1.0^C0Q
1719	"FIA",1130580001.101,1130580001.101)
1720	0
1721	"FIA",1130580001.101,1130580001.111)
1722	0
1723	"FRV1",1130580001.101,"40,7",7)
1724	MU NQF0013 HTN NUMER2 RS
1725	"FRV1",1130580001.101,"40,7",7,"F")
1726	;PXRM(810.4,
1727	"FRV1",1130580001.101,"40,7",8)
1728	MU NQF0013 HTN DENOM2 RS
1729	"FRV1",1130580001.101,"40,7",8,"F")
1730	;PXRM(810.4,
1731	"FRV1",1130580001.101,"41,7",7)
1732	MU NQF0028A TOBACCO SCREEN NUM RS
1733	"FRV1",1130580001.101,"41,7",7,"F")
1734	;PXRM(810.4,
1735	"FRV1",1130580001.101,"41,7",8)
1736	MU NQF0028B TOBACCO INTERV DENOM RS
1737	"FRV1",1130580001.101,"41,7",8,"F")
1738	;PXRM(810.4,
1739	"FRV1",1130580001.101,"42,7",7)
1740	MU NQF0041 FLU RS
1741	"FRV1",1130580001.101,"42,7",7,"F")
1742	;PXRM(810.4,
1743	"FRV1",1130580001.101,"42,7",8)
1744	MU NQF0041 FLU DENOM RS
1745	"FRV1",1130580001.101,"42,7",8,"F")
1746	;PXRM(810.4,
1747	"FRV1",1130580001.101,"43,7",7)
1748	MU NQF0024 BMI 2-17YR NUM RS
1749	"FRV1",1130580001.101,"43,7",7,"F")
1750	;PXRM(810.4,
1751	"FRV1",1130580001.101,"43,7",8)
1752	MU NQF0024 BMI 2-17YRS DEM RS
1753	"FRV1",1130580001.101,"43,7",8,"F")
1754	;PXRM(810.4,
1755	"FRV1",1130580001.101,"81,7",7)
1756	MU NQF0028B TOBACCO INTERV NUM2 RS
1757	"FRV1",1130580001.101,"81,7",7,"F")
1758	;PXRM(810.4,
1759	"FRV1",1130580001.101,"81,7",8)
1760	MU NQF0028B TOBACCO INTERV DENOM RS
1761	"FRV1",1130580001.101,"81,7",8,"F")
1762	;PXRM(810.4,
1763	"FRV1K",1130580001.101,"40,7",7)
1764	B
1765	"FRV1K",1130580001.101,"40,7",7,1)
1766	MU NQF0013 HTN NUMER2 RS
1767	"FRV1K",1130580001.101,"40,7",8)
1768	B
1769	"FRV1K",1130580001.101,"40,7",8,1)
1770	MU NQF0013 HTN DENOM2 RS
1771	"FRV1K",1130580001.101,"41,7",7)
1772	B
1773	"FRV1K",1130580001.101,"41,7",7,1)
1774	MU NQF0028A TOBACCO SCREEN NUM RS
1775	"FRV1K",1130580001.101,"41,7",8)
1776	B
1777	"FRV1K",1130580001.101,"41,7",8,1)
1778	MU NQF0028B TOBACCO INTERV DENOM RS
1779	"FRV1K",1130580001.101,"42,7",7)
1780	B
1781	"FRV1K",1130580001.101,"42,7",7,1)
1782	MU NQF0041 FLU RS
1783	"FRV1K",1130580001.101,"42,7",8)
1784	B
1785	"FRV1K",1130580001.101,"42,7",8,1)
1786	MU NQF0041 FLU DENOM RS
1787	"FRV1K",1130580001.101,"43,7",7)
1788	B
1789	"FRV1K",1130580001.101,"43,7",7,1)
1790	MU NQF0024 BMI 2-17YR NUM RS
1791	"FRV1K",1130580001.101,"43,7",8)
1792	B
1793	"FRV1K",1130580001.101,"43,7",8,1)
1794	MU NQF0024 BMI 2-17YRS DEM RS
1795	"FRV1K",1130580001.101,"81,7",7)
1796	B
1797	"FRV1K",1130580001.101,"81,7",7,1)
1798	MU NQF0028B TOBACCO INTERV NUM2 RS
1799	"FRV1K",1130580001.101,"81,7",8)
1800	B
1801	"FRV1K",1130580001.101,"81,7",8,1)
1802	MU NQF0028B TOBACCO INTERV DENOM RS
1803	"IX",1130580001.101,1130580001.101,"MU",0)
1804	1130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
1805	"IX",1130580001.101,1130580001.101,"MU",1)
1806	S ^C0Q(101,"MU",$E(X,1,30),DA)=""
1807	"IX",1130580001.101,1130580001.101,"MU",2)
1808	K ^C0Q(101,"MU",$E(X,1,30),DA)
1809	"IX",1130580001.101,1130580001.101,"MU",2.5)
1810	K ^C0Q(101,"MU")
1811	"IX",1130580001.101,1130580001.101,"MU",11.1,0)
1812	^.114IA^1^1
1813	"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
1814	1^F^1130580001.101^.3^30^1^F
1815	"MBREQ")
1816	0
1817	"PGL",1130580001.101,0,2,1)
1818	NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
1819	"PGL",1130580001.101,0,3,2)
1820	DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
1821	"PGL",1130580001.101,7,2,1.1)
1822	ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
1823	"PGL",1130580001.101,7,3,2.1)
1824	ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
1825	"PGL",1130580001.101,7,4,1.5)
1826	NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
1827	"PGL",1130580001.101,7,5,1.51)
1828	ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
1829	"PGL",1130580001.101,7,7,1.2)
1830	NUMERATOR LIST RULE^P810.4'^PXRM(810.4,^7;7^Q
1831	"PGL",1130580001.101,7,8,2.2)
1832	DENOMINATOR LIST RULE^P810.4'^PXRM(810.4,^7;8^Q
1833	"PKG",215,-1)
1834	1^1
1835	"PKG",215,0)
1836	QUALITY MEASURES^C0Q^Tracks and Prints Quality Measures
1837	"PKG",215,20,0)
1838	^9.402P^^
1839	"PKG",215,22,0)
1840	^9.49I^1^1
1841	"PKG",215,22,1,0)
1842	1.0^3120713^3120702^8
1843	"PKG",215,22,1,"PAH",1,0)
1844	3^3120713
1845	"PKG",215,22,1,"PAH",1,1,0)
1846	^^5^5^3120713
1847	"PKG",215,22,1,"PAH",1,1,1,0)
1848	Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
1849	"PKG",215,22,1,"PAH",1,1,2,0)
1850	2.0.
1851	"PKG",215,22,1,"PAH",1,1,3,0)
1852
1853	"PKG",215,22,1,"PAH",1,1,4,0)
1854	Contains updated C0Q QUALITY MEASURES file containing the appropriate
1855	"PKG",215,22,1,"PAH",1,1,5,0)
1856	rule sets to use after each measure.
1857	"QUES","XPF1",0)
1858	Y
1859	"QUES","XPF1","??")
1860	^D REP^XPDH
1861	"QUES","XPF1","A")
1862	Shall I write over your \|FLAG\| File
1863	"QUES","XPF1","B")
1864	YES
1865	"QUES","XPF1","M")
1866	D XPF1^XPDIQ
1867	"QUES","XPF2",0)
1868	Y
1869	"QUES","XPF2","??")
1870	^D DTA^XPDH
1871	"QUES","XPF2","A")
1872	Want my data \|FLAG\| yours
1873	"QUES","XPF2","B")
1874	YES
1875	"QUES","XPF2","M")
1876	D XPF2^XPDIQ
1877	"QUES","XPI1",0)
1878	YO
1879	"QUES","XPI1","??")
1880	^D INHIBIT^XPDH
1881	"QUES","XPI1","A")
1882	Want KIDS to INHIBIT LOGONs during the install
1883	"QUES","XPI1","B")
1884	NO
1885	"QUES","XPI1","M")
1886	D XPI1^XPDIQ
1887	"QUES","XPM1",0)
1888	PO^VA(200,:EM
1889	"QUES","XPM1","??")
1890	^D MG^XPDH
1891	"QUES","XPM1","A")
1892	Enter the Coordinator for Mail Group '\|FLAG\|'
1893	"QUES","XPM1","B")
1894
1895	"QUES","XPM1","M")
1896	D XPM1^XPDIQ
1897	"QUES","XPO1",0)
1898	Y
1899	"QUES","XPO1","??")
1900	^D MENU^XPDH
1901	"QUES","XPO1","A")
1902	Want KIDS to Rebuild Menu Trees Upon Completion of Install
1903	"QUES","XPO1","B")
1904	NO
1905	"QUES","XPO1","M")
1906	D XPO1^XPDIQ
1907	"QUES","XPZ1",0)
1908	Y
1909	"QUES","XPZ1","??")
1910	^D OPT^XPDH
1911	"QUES","XPZ1","A")
1912	Want to DISABLE Scheduled Options, Menu Options, and Protocols
1913	"QUES","XPZ1","B")
1914	NO
1915	"QUES","XPZ1","M")
1916	D XPZ1^XPDIQ
1917	"QUES","XPZ2",0)
1918	Y
1919	"QUES","XPZ2","??")
1920	^D RTN^XPDH
1921	"QUES","XPZ2","A")
1922	Want to MOVE routines to other CPUs
1923	"QUES","XPZ2","B")
1924	NO
1925	"QUES","XPZ2","M")
1926	D XPZ2^XPDIQ
1927	"SEC","^DD",1130580001.101,1130580001.101,3.1,9)
1928
1929	"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
1930	@
1931	"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
1932	@
1933	"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
1934	@
1935	"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
1936	@
1937	"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
1938	@
1939	"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
1940	@
1941	"VER")
1942	8.0^22.0
1943	"^DD",1130580001.101,1130580001.101,0)
1944	FIELD^^2.2^17
1945	"^DD",1130580001.101,1130580001.101,0,"DDA")
1946	N
1947	"^DD",1130580001.101,1130580001.101,0,"DT")
1948	3120712
1949	"^DD",1130580001.101,1130580001.101,0,"ID",.7)
1950	W:$D(^(5)) " ",$P(^(5),U,1)
1951	"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)
1952
1953	"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")
1954
1955	"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)
1956
1957	"^DD",1130580001.101,1130580001.101,0,"VRPK")
1958	QUALITY MEASURES
1959	"^DD",1130580001.101,1130580001.101,.01,0)
1960	NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
1961	"^DD",1130580001.101,1130580001.101,.01,.1)
1962	MEASURE NAME
1963	"^DD",1130580001.101,1130580001.101,.01,1,0)
1964	^.1
1965	"^DD",1130580001.101,1130580001.101,.01,1,1,0)
1966	1130580001.101^B
1967	"^DD",1130580001.101,1130580001.101,.01,1,1,1)
1968	S ^C0Q(101,"B",$E(X,1,30),DA)=""
1969	"^DD",1130580001.101,1130580001.101,.01,1,1,2)
1970	K ^C0Q(101,"B",$E(X,1,30),DA)
1971	"^DD",1130580001.101,1130580001.101,.01,3)
1972	Answer must be 1-30 characters in length
1973	"^DD",1130580001.101,1130580001.101,.01,"DT")
1974	3101012
1975	"^DD",1130580001.101,1130580001.101,.3,0)
1976	MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
1977	"^DD",1130580001.101,1130580001.101,.3,.1)
1978	MEANINGFUL USE YEAR KEY
1979	"^DD",1130580001.101,1130580001.101,.3,3)
1980	Answer must be 1-30 characters in length.
1981	"^DD",1130580001.101,1130580001.101,.3,"DT")
1982	3111201
1983	"^DD",1130580001.101,1130580001.101,.5,0)
1984	TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
1985	"^DD",1130580001.101,1130580001.101,.5,.1)
1986	MEASURE TITLE
1987	"^DD",1130580001.101,1130580001.101,.5,3)
1988	Answer must be 3-240 characters in length
1989	"^DD",1130580001.101,1130580001.101,.5,"DT")
1990	3110430
1991	"^DD",1130580001.101,1130580001.101,.61,0)
1992	VERY LONG DESCRIPTION^1130580001.111^^6;0
1993	"^DD",1130580001.101,1130580001.101,.7,0)
1994	DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
1995	"^DD",1130580001.101,1130580001.101,.7,.1)
1996	QRDA DISPLAY NAME
1997	"^DD",1130580001.101,1130580001.101,.7,3)
1998	Answer must be 3-240 characters in length
1999	"^DD",1130580001.101,1130580001.101,.7,"DT")
2000	3101012
2001	"^DD",1130580001.101,1130580001.101,.8,0)
2002	REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
2003	"^DD",1130580001.101,1130580001.101,.8,.1)
2004	REPORTING MEASURE NAME
2005	"^DD",1130580001.101,1130580001.101,.8,3)
2006	Answer must be 3-30 characters in length
2007	"^DD",1130580001.101,1130580001.101,.8,"DT")
2008	3110615
2009	"^DD",1130580001.101,1130580001.101,1,0)
2010	NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2011	"^DD",1130580001.101,1130580001.101,1,.1)
2012	MEASURE NUMERATOR PATIENT LIST
2013	"^DD",1130580001.101,1130580001.101,1,"DT")
2014	3101012
2015	"^DD",1130580001.101,1130580001.101,1.1,0)
2016	ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2017	"^DD",1130580001.101,1130580001.101,1.1,"DT")
2018	3110805
2019	"^DD",1130580001.101,1130580001.101,1.2,0)
2020	NUMERATOR LIST RULE^P810.4'^PXRM(810.4,^7;7^Q
2021	"^DD",1130580001.101,1130580001.101,1.2,"DT")
2022	3120712
2023	"^DD",1130580001.101,1130580001.101,1.5,0)
2024	NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2025	"^DD",1130580001.101,1130580001.101,1.5,.1)
2026	LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
2027	"^DD",1130580001.101,1130580001.101,1.5,"DT")
2028	3110809
2029	"^DD",1130580001.101,1130580001.101,1.51,0)
2030	ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2031	"^DD",1130580001.101,1130580001.101,1.51,.1)
2032	NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
2033	"^DD",1130580001.101,1130580001.101,1.51,"DT")
2034	3110809
2035	"^DD",1130580001.101,1130580001.101,2,0)
2036	DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2037	"^DD",1130580001.101,1130580001.101,2,.1)
2038	MEASURE DENOMINATOR PATIENT LIST
2039	"^DD",1130580001.101,1130580001.101,2,"DT")
2040	3101012
2041	"^DD",1130580001.101,1130580001.101,2.1,0)
2042	ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2043	"^DD",1130580001.101,1130580001.101,2.1,"DT")
2044	3110805
2045	"^DD",1130580001.101,1130580001.101,2.2,0)
2046	DENOMINATOR LIST RULE^P810.4'^PXRM(810.4,^7;8^Q
2047	"^DD",1130580001.101,1130580001.101,2.2,"DT")
2048	3120712
2049	"^DD",1130580001.101,1130580001.101,3,0)
2050	QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
2051	"^DD",1130580001.101,1130580001.101,3,.1)
2052	MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
2053	"^DD",1130580001.101,1130580001.101,3,3)
2054	Answer must be 3-120 characters in length
2055	"^DD",1130580001.101,1130580001.101,3,"DT")
2056	3101012
2057	"^DD",1130580001.101,1130580001.101,3.1,0)
2058	QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
2059	"^DD",1130580001.101,1130580001.101,3.1,.1)
2060	QRDA SYSTEM OID (FIXED)
2061	"^DD",1130580001.101,1130580001.101,3.1,9.01)
2062
2063	"^DD",1130580001.101,1130580001.101,3.1,9.1)
2064	S X="2.16.840.1.113883.3.249.12"
2065	"^DD",1130580001.101,1130580001.101,3.1,"DT")
2066	3101012
2067	"^DD",1130580001.101,1130580001.101,3.2,0)
2068	QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
2069	"^DD",1130580001.101,1130580001.101,3.2,.1)
2070	QRDA MEASURE CODE
2071	"^DD",1130580001.101,1130580001.101,3.2,3)
2072	Answer must be 1-80 characters in length
2073	"^DD",1130580001.101,1130580001.101,3.2,"DT")
2074	3101012
2075	"^DD",1130580001.101,1130580001.111,0)
2076	VERY LONG DESCRIPTION SUB-FIELD^^.01^1
2077	"^DD",1130580001.101,1130580001.111,0,"DT")
2078	3101013
2079	"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")
2080
2081	"^DD",1130580001.101,1130580001.111,0,"UP")
2082	1130580001.101
2083	"^DD",1130580001.101,1130580001.111,.01,0)
2084	VERY LONG DESCRIPTION^Wx^^0;1
2085	"^DD",1130580001.101,1130580001.111,.01,.1)
2086	LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
2087	"^DD",1130580001.101,1130580001.111,.01,3)
2088	LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
2089	"^DD",1130580001.101,1130580001.111,.01,"DT")
2090	3101013
2091	"^DIC",1130580001.101,1130580001.101,0)
2092	C0Q QUALITY MEASURE^1130580001.101
2093	"^DIC",1130580001.101,1130580001.101,0,"GL")
2094	^C0Q(101,
2095	"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)
2096
2097	END
2098	END

Note: See TracBrowser for help on using the repository browser.

Download in other formats:

Original Format